Following on from advice received from the company, NICE has decided to suspend this appraisal whilst the company confirm their regulatory filing plans in the UK.
As this appraisal has been deferred NICE will continue to monitor any development and will update interested parties if the situation changes.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3922 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 February 2024 | Suspended. Following on from advice received from the company, NICE has decided to suspend this appraisal whilst the company confirm their regulatory filing plans in the UK. As this appraisal has been deferred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 26 January 2023 | Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be scheduled to align with latest regulatory expectations and an update on the timelines will be provided when further information is available. |
For further information on our processes and methods, please see our CHTE processes and methods manual